HMGB1 and neoplasm: Moreover, in accordance with the above data showing increased geminin and not HMGB1 expression in tumor cell lines compared to naïve HME cells (Figure 1A), when the same TCGA dataset was reanalyzed instead for geminin + HMGB1 the same trend remained (i.e. geminin + HMGB1 overexpressing patients showed lower OS than low expressing HR = 1.59, 95% CI = 0.98–2.57) although the statistical significance somewhat decreased (p = 0.062, Figure 3I).